Search

Displaying results 2771 - 2780 of 8469 in total
  1. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    [A258313] The use of vardenafil as a monotherapy for the treatment of pulmonary arterial hypertension has also been evaluated.[A258308] … Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases of acute liver injury, the use of vardenafil has not been linked to hepatotoxic effects.

  2. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    receptors as opposed to dopamine receptors. … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was

  3. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  4. Drug

    Suramin

    go.drugbank.com/drugs/DB04786
    Investigational

    (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®. … It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca.

  5. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.

  6. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.

  7. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.

  8. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor. … Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

  9. Drug

    Milnacipran

    go.drugbank.com/drugs/DB04896
    ApprovedInvestigational

    -1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease [A175957]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment

  10. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.